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Abstract
Background: Ovarian cancer is mostly associated with pathologically regulated permeability of peritoneal vessels,
leading to ascites. Here, we investigated the molecular regulation of endothelial permeability by the vascular
endothelial growth factor (VEGF) and both tight and adherens junction proteins (VE-cadherin and claudin 5) with
regards to the tumor biology of different ovarian cancer types.
Methods: Serum and ascites samples before and after surgery, as well as peritoneal biopsies of 68 ovarian cancer
patients and 20 healthy controls were collected. In serum and ascites VEGF protein was measured by ELISA. In
peritoneal biopsies co-localization of VE-cadherin and claudin 5 was investigated using immunohistochemical dual
staining. In addition, the gene expression of VE-cadherin and claudin 5 was quantified by Real-time PCR. Differences
in VEGF levels, VE-cadherin and claudin 5 gene expression were analyzed in relation to various tumor characteristics
(tumor stage, grading, histological subtypes, resection status after surgery) and then compared to controls.
Furthermore, human primary ovarian cancer cells were co-cultured with human umbilical vein endothelial cells
(HUVEC) and changes in VE-cadherin and claudin 5 were investigated after VEGF inhibition.
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Results: VEGF was significantly increased in tumor patients in comparison to controls and accumulates in ascites.
The highest VEGF levels were found in patients diagnosed with advanced tumor stages, with tumors of poor
differentiation, or in the group of solid / cystic-solid tumors. Patients with residual tumor after operation showed
significantly higher levels of VEGF both before and after surgery as compared to tumor-free resected patients.
Results of an immunohistochemical double-staining experiment indicated co-localization of VE-cadherin and
claudin 5 in the peritoneal vasculature. Compared to controls, expression of VE-cadherin and claudin 5 was
significantly suppressed in peritoneal vessels of tumor patients, but there were no significant differences regarding
VE-cadherin and claudin 5 expression in relation to different tumor characteristics. A significant positive correlation
was found between VE-cadherin and claudin 5 expression. VEGF inhibition in vitro was associated with significant
increase in VE-cadherin and claudin 5.
Conclusions: Our results indicate that increased peritoneal permeability in ovarian cancer is due to down-
regulation of adhesion proteins via tumor derived VEGF. Advanced ovarian cancer with aggressive tumor biology
may be associated with early dysregulation of vascular permeability leading to ascites. These patients may benefit
from therapeutic VEGF inhibition.
Keywords: Ovarian cancer, Vascular permeability, Ascites, VEGF, VE-cadherin, Claudin 5
Background
Ovarian cancer is heterogeneous in nature, characterized
by differences in tumor growth and survival [1]. Sub-
types of more or less aggressiveness are low (LGSOC)
and high grade (HGSOC) serous ovarian carcinoma,
endometrioid, clear cell and mucinous ovarian cancer
[2]. LGSOC is often detected in an early tumor stage
and accompanied with well differentiated histology [3].
It may be found incidentally during routine ultrasound
or during an operation of another indication [4]. Patients
with LGSOC may stay progression free over many years
until a new relapse occurs. In contrast, HGSOCs are
well known to represent an extremely aggressive, fast-
growing cancer usually diagnosed in an advanced tumor
stage and carrying poor prognosis compared to other
histological subtypes [5, 6]. Often the first clinically no-
ticeable symptom seen in these patients is an increase in
abdominal circumference due to high-volume ascites
production [7]. The ascites may lead to an intra-
abdominal pressure increase with subsequent abdominal
pain, nausea, shortness of breath or bowel obstruction
[8]. Thus, quality of life of these patients is often ex-
tremely limited.
We recently showed for serous papillary ovarian can-
cer patients that the reason for ascites production is a
dysregulated endothelial barrier function of the periton-
eal vasculature which leads to an increase of vascular
permeability [9]. The endothelial barrier for fluids is
built by cell adhesion proteins. Here, adherens junction
proteins such as VE-cadherin or tight junction proteins
such as claudin 5 seal the space between endothelial
cells more or less tightly in dependency of their expres-
sion strength. In our recent study, we detected increased
levels of the vascular endothelial growth factor/vascular
permeability factor (VEGF), a potent cytokine and key
regulator of physiological and pathological angiogenesis,
in the ascites and serum of ovarian cancer patients asso-
ciated with a simultaneous decreased amount of the
tight junction protein claudin 5 in the peritoneal vessels
[9]. In an in vitro model we showed a VEGF-dependent
decrease of claudin 5 followed by a significant increase
of endothelial permeability, thus ascites production [9].
Besides, a VE-cadherin-dependent expression of claudin
5 in endothelial cells has been reported via the transcrip-
tion factor FoxO1 [10]. For permeability regulation in
the human corpus luteum we previously found that
under hCG influence VEGF induces down-regulation of
a cascade of adhesion proteins: VEGF dependent down-
regulation of VE-cadherin is followed by suppression of
other adhesion proteins such as claudin 5, consequently
resulting in increased permeability [11].
Given that different ovarian cancer subtypes are asso-
ciated with variable clinical manifestations and amounts
of ascites production, the aim of the present study was
to evaluate whether our previously observed mechanism
of interaction between VEGF-A165 (hereafter named
VEGF) - the most important angiogenic factor - and ad-
hesion proteins in serous papillary cancer patients varies
depending on histological type and tumor biology. In
addition, we focused on the question if under VEGF in-
fluence VE-cadherin is interacting with claudin 5 for
permeability regulation. More specifically, we investi-
gated VEGF levels in serum and ascites as well as pro-
tein and gene expression of VE-cadherin and claudin 5
in peritoneal vessels of ovarian cancer patients in rela-
tion to the prognostic factors tumor stage, histological
type, tumor grading and resection status after surgery.
Moreover, we simulated the in vivo situation for the first
time in a co-culture model with human ovarian cancer
cells extracted from ovarian cancer patients of our
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department, and investigated the changes of VE-
cadherin and claudin 5 after VEGF inhibition.
Results
Patient characteristics
In total 68 patients with ovarian cancer and 20 healthy
controls have been collected and analyzed. The patient
age ranged from 49 to 77 years for the cancer group and
from 49 to 66 years for the controls.
Histopathologic tumor characteristics
Most ovarian cancer patients presented with serous
papillary ovarian cancer (68 %), followed by mixed type
tumors (13 %), endometrioid (7 %), solid/cystic-solid
(6 %) and mucinous tumors (6 %). 47 % of the patients
had an advanced tumor disease (FIGOIIIc). There were
75 % of the ovarian cancer patients with poorly differ-
entiated tumors (G3), 20 % presented with moderately
tumor differentiation (G2) and 5 % of the patients had
well differentiated tumors (G1). Concerning the post-
operative remaining tumor, 55 % of our analyzed pa-
tient collective were operated tumor free (TR 0), 28 %
had residual tumor left <1 cm and 18 % of the patients
had rest tumor >1 cm.
VEGF-concentration in serum according to time and
tumor characteristics
Measurement of VEGF in the serum of ovarian cancer
patients on day 0 revealed significant (p = 0.013) higher
values as compared to healthy controls (Fig. 1a). The
analysis of VEGF levels in the serum of ovarian cancer
patients at day 2 after surgery revealed a significant
(p < 0.001) decrease as compared to day 0, while at day 4
after surgery a significant (p < 0.001) increase of VEGF
levels of tumor patients could be observed (Fig. 1b).
Patients with larger tumors (T3-4) had higher serum
VEGF levels compared to patients with smaller tumors
(T1-2) at all days of measurement (day 0, day 2 and day
4; all p > 0.07; Fig. 2a). In the group of T3-4 tumors,
significant differences in VEGF serum levels could be
shown among all three measurement days of measure-
ment, with a significant decrease on day 2 and a signifi-
cant increase on day 4 (all p < 0.003) (Fig. 2a). However,
in the group of T1-2 tumors VEGF serum levels differed
significantly only between day 0 and day 2 (p =0.028)
and between day 2 and day 4 (p = 0.043).
The analysis of serum VEGF in the ovarian cancer pa-
tient group with no residual tumor after surgery (TR 0)
and remaining tumor (TR >1 cm or TR <1 cm) revealed
that both the group with residual tumor <1 cm and the
group with residual tumor >1 cm had significant higher
values of serum VEGF at day 0 in comparison to the
group with no remaining tumor (p = 0,049 and p = 0,003,
respectively) (Fig. 2b). The highest values were measured
in the group with residual tumor left after operation >1
cm. Significant (all p < 0.02) differences between the
various days of measurement (0, 2 and 4 days) were de-
tected in all three groups (TR 0, TR <1 cm, TR >1 cm).
(Fig. 2b) with a decrease in serum VEGF at day 2 and an
increase on day 4 (Fig. 2b).
Fig. 1 VEGF levels in serum (tumor vs. control) and at different days of measurement (tumor samples). Comparison of VEGF levels (pg/ml) in serum
samples between tumor and control group. Statistically significant higher amounts of VEGF levels were detected in the tumor group (p = 0.013) (a).
VEGF levels in serum in the tumor samples before operation (day 0), two days (day 2) and four days (day 4) after surgery. There were statistically
significant differences between all days of measurement, with a decrease of VEGF levels at day 2 and increase at day 4 of measurement (all
p < 0.001) (b)
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The comparison between VEGF values in the serum of
different histological types of ovarian cancer revealed no
significant differences. Furthermore, no significant differ-
ences in the levels of VEGF could be detected between
ovarian cancer patients with different tumor grading
(G1/G2 vs. G3), different nodal status (N0 vs. N1) or dif-
ferent hormone receptor status (ER/PGR positive vs.
negative).
VEGF-concentration in ascites according to time and
tumor characteristics
Since we supposed that the tumor itself might be the main
source of VEGF, the concentration of VEGF was measured
in the ascites at day 0, 2, and 4 after surgery. A significant
decrease of VEGF was observed between day 0 and day 2
(p < 0.001) as well as between day 0 and day 4 (p < 0.001)
with no difference between day 2 and day 4 (p = 0.320).
Patients with T3-4 tumors had significantly higher
levels of VEGF in ascites on day 0 in comparison to
patients with T1-2 tumors (p < 0.001) (Fig. 3a); and
there was a trend towards higher VEGF levels on day
0 in patients with poorly differentiated tumors (G3) in
comparison to well or moderately differentiated tu-
mors (G1/G2) (p = 0.061) (Fig. 3b). Measurement of
VEGF levels in the ascites of patients with different re-
section status after surgery revealed higher levels in
patients with residual tumor after surgery (TR <1 cm and
TR >1 cm) in comparison to patients with no remaining
tumor (TR 0) at all three measurement days (Fig. 3c). The
differences between the group of patients with remaining
tumor <1 cm and the group with no residual tumor were
significant at all days of measurement (all p < 0.05), and
the differences between the group of patients with residual
tumor >1 cm and the group with no residual tumor were
significant on day 2 (p = 0.002) and on day 4 (p = 0.006)
but not on day 0 (p = 0.063). There were no significant dif-
ferences with regard to VEGF levels in ascites between the
group of patients with residual tumor <1 cm and the
group of patients with residual tumor >1 cm at any of the
three days (all p > 0.05). A significant decrease of VEGF
levels between day 0 and 2 could be detected in patients
with no remaining tumor (p = 0.001) and patients with
remaining tumor <1 cm (p = 0.009), but not in patients
with residual tumor >1 cm (p = 0.499). The comparison
between VEGF values in the ascites of different histo-
logical types of ovarian cancer on day 0 of measure-
ment revealed significant differences (p = 0.039) with
highest levels observed in the group of cystic solid tu-
mors (Fig. 3d).
VE-cadherin and claudin 5 in the peritoneal vessels
Dual staining for VE-Cadherin or claudin 5 with CD 31
revealed that both proteins are localized to peritoneal
vessels. Furthermore, dual staining for VE-Cadherin with
claudin 5 clearly showed the co-existence of both pro-
teins in the same vessel (Fig. 4a-c). In the peritoneal
vasculature of tumor patients VE-Cadherin and claudin
5 protein are clearly down-regulated as indicated by an
Fig. 2 VEGF levels in serum in relation to tumor stage and resection status after surgery. Comparison of VEGF levels (pg/ml) between different
groups of tumor sizes (T1-2 vs. T3-4) on the different days of measurement (day 0, day 2 and day 4) showed numerically but not significantly
higher values in the group of T3-tumors compared to T1-ovarian cancers (all p > 0.07). The differences between the different days of measurement
(decrease at day 2 and increase at day 4) were significant in the T3-group (p< 0.003) (a). Analysis of VEGF levels in the ovarian cancer patient group with
no residual tumor after surgery (TR 0) and remaining tumor (TR > 1 cm or TR < 1 cm). We revealed significant higher values in the group with residual
tumor (both < and > 1 cm) in comparison to the group with no remaining tumor measured before operation at day 0 (p= 0.049 and p= 0.003). Significant
(all p< 0.02) differences between the various days of measurement (0, 2 and 4 days) were detected in all three groups (TR 0, TR < 1 cm, TR > 1 cm), with a
decrease in serum VEGF levels at day 2 and an increase on day 4 (b)
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unevenly distributed staining (Fig. 4d-f ). While in con-
trols dual staining is generally found in nearly all vessels
in tumor patients dual staining is generally weaker and
varies a lot.
As we had already demonstrated a significant reduction
for claudin 5 levels in the peritoneal vessels of ovarian
cancer patients as compared to the controls in a former
study [9] we here performed an analysis on the level of
gene expression. Real-time PCR revealed significant
(p < 0.001) lower values of VE-cadherin as well as claudin
5 expression in the peritoneal vessels as compared to the
healthy control group (Fig. 5). Plotting the values of VE-
cadherin and claudin 5 in the peritoneal samples against
each other we found a significant (rS = 0.839, p < 0.001)
positive correlation (Fig. 6a), suggesting that VE-cadherin
and claudin 5 levels are regulated in a similar way. In con-
trast, VEGF levels in ascites at day 0 were negatively cor-
related to both VE-cadherin and claudin 5 expression
Fig. 3 VEGF levels in ascites in dependency of tumor stage, grading, resection status and histological type. Comparison between VEGF levels (pg/ml)
in the ascites samples of ovarian cancer patients between tumors of different sizes (T1-2 vs. T3-4). Statistically significant higher values in patients with
T3-4 tumors were detected in comparison to T1-2 tumors (day 0) (p < 0.001) (a). Comparing VEGF levels in the ascites samples of ovarian cancer
patients with well or moderately differentiated (G1/G2) and poorly differentiated (G3) tumors, we found a trend for higher values in patients with G3-
tumors in comparison to G2/G1-tumors (day 0) (p = 0.061) (b). We revealed higher levels in patients with residual tumor after surgery (TR < 1 cm and TR >
1 cm) at day 0 in comparison to patients with no remaining tumor (TR 0). The differences between the group of patients with remaining tumor < 1 cm
and the group with no residual tumor were significant at all days of measurement (all p< 0.05), and the differences between the group of patients with
residual tumor > 1 cm and the group with no remaining tumor were significant on day 2 (p= 0.002) and on day 4 (p= 0.006) but not on day 0 (p= 0.063).
There were no significant differences with regard to VEGF levels in ascites between the group of patients with remaining tumor < 1 cm and the group of
patients with remaining tumor > 1 cm at any of the three days (all p> 0.05). A significant decrease of VEGF between day 0 and 2 could be detected in
patients with no remaining tumor (p= 0.001) and patients with residual tumor < 1 cm (p= 0.009), but not in patients with remaining tumor > 1 cm (p=
0.499). (c). Analysis at day 0 of measurement revealed highest levels in the group of solid / solid-cystic tumors (d)
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in the peritoneal vessels (VE-c: rS = −0,384, p = 0.012)
(cl 5: rS = −0.355, p = 0.021); the scatter plots indicate
that there might be a hyperbolic function rather than
a linear relationship in both cases (Figs. 6b and c).
Interestingly, analysis of VE-cadherin and claudin 5
expression in the peritoneal vessels in relation to various
tumor characteristics (i.e. tumor stage, grading, histo-
logical type) revealed no significant differences.
Analysis in human ovarian cancer cells and HUVEC in the
co-culture-system
For the use of our human ovarian cancer cell line in co-
culture we first of all confirmed that the cells express the
VEGF gene and secrete VEGF in the culture medium by
ELISA. Since it has been shown in vivo that the adhesion
proteins VE-cadherin and claudin 5 are reduced in the
peritoneal vessels of ovarian cancer patients, we measured
Fig. 4 Claudin 5 and VE-Cadherin in the peritoneal vessels (ovarian cancer vs. control). Representative immunocytochemical staining of claudin 5
(green staning), VE-Cadherin (red staining) and their co-localisation (orange staining) in the peritoneal tissue (a-c control, d-f ovarian cancer). Note
the general occurrence of both proteins in the endothelium of the same vessels in controls (c). In contrast in tumors the staining is generally
weaker and discontinuously distributed (arrows). Some of the vessels lack one of the proteins (e.g. claudin 5) (arrowhead). Pictures are taken with
fluorescence microscope under 40× magnification
Fig. 5 Expression of claudin 5 and VE-cadherin in the peritoneum (tumor vs. control). Real-time PCR-analysis of claudin 5 and VE-cadherin in the
peritoneal vessels of ovarian cancer patients. We revealed statistically significant lower values of claudin 5- and VE-cadherin-expression in the
peritoneal vessels of the tumor patients as compared to the healthy control group (both p < 0.001)
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the production of VE-cadherin and claudin 5 in HUVEC
grown in the co-culture system in vitro. Confirming the
results of our previous studies in a co-culture model with
synthesized Ovcar-3 cells we found a significant (p < 0.05)
decrease of claudin 5 in HUVEC co-cultured with our
human ovarian cancer cells, which was prevented by sim-
ultaneous treatment with the VEGF-inhibitor Flt1-Fc. In
addition, for VE-cadherin a comparable significant
(p < 0.05) decrease in HUVEC co-cultured with our
human ovarian cancer cells was detected, which was
prevented by simultaneous treatment with the VEGF-
inhibitor Flt1-Fc. Figures 7a and b illustrate these results.
Discussion
Ascites as a sign of advanced tumor growth reduces the
quality of life of ovarian cancer patients [8, 12]. Malignant
ascites is known to arise from both tumor surface and
tumor peritoneum [13]. This metastatic pattern is
dependent on establishing angiogenesis at the newly seeded
site [14]. Here VEGF plays an important role by promoting
neovascularization and enhancing vascular permeability,
thus leading to intraabdominal tumor growth, tumor
spread, peritoneal carcinomatosis and ascites formation
[15]. Previously we demonstrated a potential mechanism of
ascites production in serous ovarian cancer patients by
VEGF affecting tight junctions in the peritoneal vasculature
[9]. In the current study we demonstrate for the first time,
that VEGFA, known as the most important angiogenic fac-
tor, is differentially expressed in dependency of tumor stage,
grading, histological type and surgical resection status, with
highest expression in advanced tumor stage (T3-4), poorly
differentiated tumors (G3), solid tumors and after resection
Fig. 6 Correlation between adhesion protein expression (VE-cadherin and claudin 5) and VEGF in the peritoneum. Correlation between claudin 5
and VE-cadherin in the peritoneum of ovarian cancer patients. By plotting the values of real-time PCR-analysis against each other a significant lin-
ear correlation between claudin 5 and VE-cadherin was detected (rS = 0.839, p < 0.001) (a). Plotting the VEGF expression against VE-cadherin or
claudin 5 expression showed significant negative correlations (VE-c: rS = −0,384, p = 0.012) (cl 5: rS = −0.355, p = 0.021); the scatter plots indicate
that there might be a hyperbolic function rather than a linear relationship in both cases (b and c)
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with residual macroscopic disease (TR). In addition, we
demonstrate that under the influence of tumor derived
VEGF different cell adhesion types (tight and adherens
junctions) interact in the peritoneal vasculature to regulate
endothelial permeability. The down regulation of adherens
junctions (VE-cadherin) and subsequent suppression of
tight junctions (claudin 5) by VEGF, which is accumulated
in serum and ascites, may account for the massive loss of
fluid into the abdominal cavity in advanced ovarian cancer.
The current study confirmed our previously obtained
preliminary observations obtained on 10 tumor patients
[9]. In consistency with the former study, VEGF was
significantly increased in the serum as well as in ascites
of preoperative ovarian cancer patients as compared to
healthy controls. These findings are consistent with
other investigations of VEGF levels in ovarian cancer in
comparison to benign cystadenomas [16–18]. VEGF is
known to be expressed to a great extent in the majority
of ovarian cancers and its risen serum levels and tumor
levels have been found to be independent markers of
poor clinical outcome [19]. In addition, elevated VEGF
levels in malignant ascitic fluids were reported to be of
prognostic significance [20]. Our results indicate that
VEGF does not only play a local role (in the abdomen
via regulation of endothelial permeability and ascites for-
mation) but also a systemic role (blood) in ovarian can-
cer patients. VEGF secreted into the bloodstream may
possibly interact on the vasculature of other serous tis-
sue, such as pleura. This may explain that sometimes
pleural effusion is observed in ovarian cancer patients
without any tumor affection of the pleura [21].
Consistent with our previous study, measurement of
VEGF in the serum preoperative, on day 2 and 4 after
surgery revealed a significant decrease of VEGF levels
2 days after surgery and a significant increase at day 4
[9]. The effect of tumor reduction via surgery is clearly
reflected by a significant decrease of the VEGF amount
in the serum and ascites two days after surgery. How-
ever, the increase of serum VEGF at day 4 after surgery
appears to be paradox, especially since this increase was
not observed in the ascites samples. This finding may be
explained by the fact, that after surgery wound healing
and tissue regeneration processes occur which are asso-
ciated with increase in angiogenesis induced by VEGF
that is now synthesized by other tissue and released sys-
temically [22–24].
As a main focus of this study, the potential differences
of permeability regulation in dependency of varying tumor
stage, grading, histological ovarian cancer subtypes and
resection status after surgery were investigated. In this
study we detected for the first time differences of VEGF
synthesis in various histological and biological tumor
types. Regarding the histological type, ascites samples re-
vealed significant highest VEGF levels in patients with
solid tumors which are associated with worse clinical out-
come and more aggressiveness in tumor growth [25] as
compared to the group of serous, endometrioid, mucinous
and mixed-type tumors. Moreover, we revealed higher
values of VEGF levels in serum and ascites samples of
patients with ovarian cancer of advanced tumor stages
(T3-4 tumors) indicating that the VEGF level correlates
positively with the total tumor mass. VEGF is known to
be the most important angiogenic factor promoting tumor
growth through stimulation of angiogenesis [26]. Through
this mechanism tumor-derived VEGF enhances the peri-
toneal vasculature permeability leading to the formation
of malignant ascites, tumor spread, dissemination and
growth as well as formation of peritoneal metastasis.
Fig. 7 Changes of adhesion proteins co-cultured with HUVEC and ovarian cancer cells. Co-culture model of human ovarian cancer cells with
HUVEC without (dark grey bar) and with (light grey bar) VEGF-inhibition via Flt1-Fc. Changes in claudin 5 and VE-cadherin were measured using
Real-time PCR. VEGF inhibition revealed a significant increase of claudin 5 and VE-cadherin in comparison to the co-culture without inhibition
(both p < 0.05) (a and b)
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Bryne et al. reported that enforced expression of VEGF by
ovarian cancer cells dramatically reduced the time to on-
set of ascites formation [27]. This is in line with the clin-
ical observation that ovarian cancer types of early stage
often do not present with ascites formation [3]. It may be
hypothesized that there exists a critical tumor mass which
produces enough VEGF for ascites production. This hy-
pothesis is further supported by our finding that VEGF
levels tended to be higher in ascites of patients with poorly
differentiated tumors (G3) as compared to well or moder-
ately differentiated tumors (G1/G2). Poorly differentiated
tumors are growing faster according to high tumor cell
proliferation. These patients with poorly differentiated tu-
mors are often diagnosed in advanced tumor stages i.e.
with high tumor load. The aggressiveness of these tumors
leading to increased VEGF may facilitate local metastasis
in the peritoneum by induction of angiogenesis so that the
tumor may be early connected and spread via the vascular
system [17, 28, 29].
Our results concerning the different tumor resection
status after surgery (no residual tumor, remaining
tumor <1 cm or >1 cm) further support the fact that the
total tumor mass is critical for VEGF secretion. Here,
we found a positive correlation between tumor load
and VEGF levels both in serum and ascites samples
with higher values of VEGF in the patient group with
residual tumor in comparison to those being success-
fully operated tumor free. This difference in VEGF
levels could be detected for all days of measurement,
before (day 0) as well as day 2 and 4 after surgery.
Highest levels of VEGF were detected in the group of
patients with the largest residual tumor (TR >1 cm).
Concerning clinical systemic treatment guidelines of
ovarian cancer, these results underline the effectiveness
of anti-angiogenic therapies such as VEGF-antibody
therapies in patients with advanced tumor stages and
remaining tumor [30]. Since the VEGF levels of patients
with a final residual tumor after operation are already
elevated in serum and ascites before surgery (day 0) in
comparison to those with no postoperative residual
tumor, the question arises whether differences in VEGF
expression could predict which of the patients will be
successfully operated tumor free.
Ascites production due to increased peritoneal per-
meability appears to be dependent on suppression of
cell adhesion proteins [9]. For instance, inhibition of
VE-cadherin leads to a dissolution of tight junctions
and thus secondary to increased vascular permeability
[11]. At the same time a VEGF-dependent regulation of
the junctional protein claudin 5 with a consecutive in-
crease of permeability was detected in our previous
studies in an in vitro corpus luteum model [31] and in
serous ovarian cancer [9]. Based on these data, we as-
sumed a functional role of VEGF-dependent regulation
of VE-cadherin and claudin 5 concerning regulation of
endothelial permeability also in the peritoneal tissue of
ovarian cancer patients. In order to investigate this pre-
sumption, a new co-culture system of human ovarian
cancer cells (to simulate the conditions in vivo) and
endothelial cells (HUVEC) was used. As expected, due
to VEGF produced by the ovarian cancer cells, endo-
thelial cells co-cultured with our human ovarian cancer
cells presented with significant lower levels of VE-
cadherin and claudin 5. This effect was prevented by
simultaneous treatment with the VEGF-inhibitor Flt1-
Fc validating the functional dependence between VEGF
and the adhesion proteins. For the in vivo situation we
detected VE-cadherin being co-localised with claudin 5
in the majority of the peritoneal vessels. Expression of
both molecules was in general significantly decreased
in the peritoneum of ovarian cancer patients. In
addition, some of the vessels or parts of the peritoneal
endothelium lack one of these proteins completely indi-
cating the disturbance of normal cell adhesion resulting
in increased permeability and ascites formation. Re-
garding the interaction of VE-Cadherin and claudin 5
we found a significant positive correlation for expres-
sion of both adhesion proteins, indicating that both
membrane proteins are regulated similarly and that
they may interact with each other, as described by other
studies [10].
Since we proved in vitro the functional influence of
VEGF on expression of cell adhesion proteins and we found
in situ higher VEGF levels in solid tumors, T3-4 and G3
tumors, we hypothesized that in these subtypes VE-
cadherin and claudin 5 are significantly more suppressed as
compared to the other subtypes. However, we did not find
any differences in gene expression between different histo-
logical subtypes, tumor stages or grading. It was further-
more suspected that VE-cadherin and claudin 5 were
negatively correlated to the VEGF levels. Indeed, our ana-
lyses revealed significant negative correlations between
VEGF levels and the expression of adhesion proteins (both
VE-cadherin and claudin 5); however, the scatter plots indi-
cated a hyperbolic function rather than a linear relationship.
This indicates that as soon as a certain threshold value of
VEGF is reached gene expression of the VE-cadherin and
claudin 5 is switched off and no further increase of VEGF is
necessary to have a further suppressive influence on these
membrane proteins.
Overall, our findings suggest that ovarian cancer cells
produce VEGF in order to first induce angiogenesis to allow
tumor growth and second increase endothelial permeability
via suppression of VE-cadherin and subsequent claudin 5
in the peritoneal vasculature, which finally induces ascites
and thereby facilitates dissemination of cancer cells in the
abdominal cavity. Since aggressive and advanced tumors
synthesise significantly more VEGF, dissemination of cancer
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cells may be facilitated and thus metastases may develop
earlier than in less aggressive tumors, which is in accord-
ance with the poor prognosis of the aggressive tumor
subtypes.
Conclusions
In summary, our results demonstrate that VEGF plays
an important role in pathological hyperpermeability
and ascites formation of human ovarian cancer via
down-regulation of a cascade of adhesion proteins
(VE-cadherin and subsequent claudin 5). Increased
VEGF levels were associated with histologic solid
tumors, high (T3-4) tumor load, poor tumor differen-
tiation and tumor rest after surgery in serum and/or
ascites samples. Thus, it is assumed that advanced
ovarian cancer types are characterized by early dysreg-
ulation of vascular permeability leading to ascites and
tumor spread. These patients may mostly benefit from
therapeutic VEGF inhibition. In addition, measure-
ment of early post-surgical serum VEGF levels may




The tumor- and peritoneal tissue as well as serum and
ascites samples used for the experiments were collected
from patients undergoing laparotomy for ovarian cancer.
Tumor and peritoneal tissue samples were collected dur-
ing surgery in liquid nitrogen for further RNA-isolation
and in 3.5–3.7 % formaldehyde (Fischar, Saarbrücken,
Germany) for immunohistochemistry. In addition, serum
and ascites samples of all subjects were collected before
surgery (day 0) as well as two days (day 2) and four days
(day 4) after surgery. As controls, we used tissue samples
of patients undergoing surgery for benign reasons such
as uterine myoma or uterine prolapse.
The collection and use of human tissue, ascites and
serum was institutionally approved by the Ethics
Committee of the University of Ulm and the patients
had given their informed consent.
Preparation of tissue for H&E staining and
Immunhistochemistry
The tumor- and peritoneal tissue samples were fixed in
3.5–3.7 % formaldehyde (Fischar, Saarbrücken, Germany)
for 24 h and then incubated in 70 % ethanol at room
temperature overnight. Afterwards the tissue was dehy-
drated for 45 min at 40 °C in ascending concentrations of
ethanol, then 2 x 45 min of xylol and in the end 2 x
60 min in Paraplast Plus (Tissue Embedding Medium,
Leica, Richmond, USA).
Morphological characterization of ovarian cancer
Consecutive sections stained for hematoxylin and eosin
were used to classify the ovarian cancer and peritoneal
tissue. Therefore, the embedded ovaries were serially
sectioned, and tissue sections (3 μm) were placed onto
SuperFrost Plus slides (VWR, Leuven, Belgium). Tissue
sections were dewaxed in xylene, rehydrated in descend-
ing concentrations of ethanol, washed in distilled water,
and stained with hematoxylin (Mayer’s hemalum solu-
tion, Merck, Darmstadt, Germany) for 3 min, followed
by a rinsing with hydrochloric acid 0.1 % and by a wash
in water and acetic alcohol before staining with eosin
(Eosin Y-solution 0.5 % aqueous, Merck, Darmstadt,
Germany) for 3 min. After dehydrating in ascending
concentrations of ethanol and xylene, sections were
mounted in Eukitt (Kindler, Freiburg, Germany).
The final tumor staging (TNM classification) was ob-
tained from the report of the institutional pathologist
and documented for each ovarian cancer patient for later
analysis. Data on the intraoperative resection status of
each tumor patient were obtained from the operation
report.
Immunohistochemistry dual staining (VE-cadherin and
claudin 5)
Immunofluorescence double-staining was performed
using the TSA-Kit (Perkin Elmer, Boston, USA). Sections
of paraffin-embedded peritoneal tissue were dewaxed
and rehydrated using xylol and ethanol, respectively, and
transferred to TN-buffer. Slides were incubated in Target
Retrieval Solution pH 9 (1:10) at 95 °C for 30 min in the
water bath, left in the hot buffer for another 20 min,
cooled down and transferred to TN-buffer for 5 min.
Endogenous peroxidase was quenched for 30 min in
180 ml methanol + 20 ml hydrogen peroxide (30 %), and
slides were again transferred to TN-buffer for 5 min. After
pre-incubation with TNB for 30 min, the slides were incu-
bated with the mouse anti-human CD 31 antibody (Dako,
Hamburg, Germany; 1:30 dilution) over night at 4 °C to
prove the co-localization to the endothelial compartment
in the further step. The slides were then washed in TN-
buffer with 0.1 % Tween for 3 × 5 min, followed by incuba-
tion with biotinylated rabbit anti mouse secondary antibody
(Dako, Hamburg, Germany; dilution 1:750) for 45 min.
Washing in TN-buffer + Tween and incubation with
SA-horse-radish peroxidase (HRP) and Fluoresceine
tyramide was performed according to the instructions
of the manufacturer. Incubation with the second
primary antibody, the antibody mouse anti-human
VE-cadherin (Merck Millipore, Darmstadt, Germany;
dilution 1:20) or the antibody mouse anti-human clau-
din 5 (Invitrogen, Carlsbad, USA; dilution 1:100), over-
night at 4 °C was followed by washing, incubation with
biotinylated secondary antibody, SA-HRP and TMR
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tyramide as described above. Mounting was performed
with Roti-Mount FlourCare. In order to prove co-
localization of VE-cadherin with claudin 5 in the same
vessel double-staining was performed as described above
using claudin 5 instead of CD 31. Pictures were taken with
Keyence fluorescence microscope BZ-9000 under 40×
magnification.
Quantification of VEGF by ELISA (serum and ascites)
The analysis of our study was focused on the most import-
ant pro-angiogenic factor VEGF-A (splice variant 165). In
order to quantify the secreted amount of VEGF, a quanti-
tative VEGF immunoassay was performed according to
the manufacturer’s protocol (R&D Systems, Minneapolis,
USA). Briefly, 100 μl of control, sample or standard was
added to 100 μl assay diluent. After 2 h incubation at
room temperature, the samples were washed three times.
Then 200 μl VEGF conjugate was added for 2 h and the
samples were washed again. After incubation with 200 μl
substrate solution for 25 min, 50 μl stop solution was
added and the optical density was measured at 450 nm
(Elisareader Sunrise, Tecan, Männedorf, Switzerland).
Endothelial cell isolation and culture
The collection of human primary cells was institutionally
approved after favorable ethical review. Human umbil-
ical cords were rinsed with water and disinfected with
isoseptol. Under sterile conditions the ends of the cords
were cut and into each end a flexible tube was inserted
and fixed with a cable tie. The umbilical veins were
rinsed with phosphate buffered saline (1 x PBS). One
end was clamped and from the other end the vein was
filled with type 1 collagenase (1 mg/ml; Sigma, Saint
Louis, USA) to detach the endothelial cells. Subse-
quently, the second end was clamped and the cords were
incubated in a water bath at 37 °C for 15 min.
Human umbilical vein endothelial cells (HUVEC)
were collected and mixed 1:1 with endothelial cell
growth medium (Promocell C-22010, Heidelberg,
Germany) + 10 % fetal calf serum (FCS) with 1 %
penicillin/streptomycin (Gibco by Life Technologies,
Carlsbad, USA). After centrifugation for 5 min at
1200 rpm the supernatant was discarded and the
pellet was resuspended in culture medium. The
HUVEC were seeded either in primaria tissue flasks
(25 cm2) or in 6-well plates and incubated at 37 °C
in 5 % CO2.
Cell culture for human ovarian cancer cells
In order to work with human ovarian cancer cells we
used ovarian cancer cell lines of our department, which
have been established before by Möbus et al. [32].
For our experiments the human ovarian cancer cells
were cultivated in DMEM with GlutaMax (Gibco by Life
Technologies, USA) with 1 % Penicillin/Streptomycin
10 % FCS (FBS superior, Biochrom, Berlin, Deutschland).
Media were changed twice a week.
Co-culture of ovarian cancer cells and HUVEC
For our co-culture experiments we used our well-
established co-culture model by Herr et al. [9]. Instead
of treatment with conventional ovarian cancer cell-lines
we used a co-culture system with HUVEC and our hu-
man ovarian cancer cell lines. Treatment involved first a
negative control with HUVEC only, second the co-
culture with ovarian cancer cells and HUVEC and third
VEGF-inhibition by addition of Flt1-Fc (VEGF-Receptor-
1 (Flt-1)/Fc Chimera, Mouse, recombinant; Steinheim,
Germany) to both cell compartments. Figure 8 illustrates
the co-culture setting.
HUVEC (2x105 per well) were seeded onto 6-well
plates and grown to 90–100 % confluency. On the same
day of culture, human ovarian cancer cells (2 x 105 cells)
were transferred to cell culture inserts (0.4 μm pore size,
Becton Dickinson Nr. 353090). On day 2, cell culture in-
serts with human ovarian cancer cells were inserted into
the 6-well plates with HUVECs in culture. Endothelial
cells were treated with 200 ng and ovarian cancer cells
with 300 ng Flt1-Fc. In this setting, molecules secreted
by ovarian cancer cells follow the concentration gradient
between the two different media such that the HUVEC
can be stimulated.
Fig. 8 Co-culture of ovarian cancer cells and HUVEC. Schematic drawing illustrating the co-culture model of HUVEC (green) separated from the
human ovarian cancer cells (blue) by a permeable membrane (pore size 0.4 μm). Treatments involved a negative control with HUVEC and an
empty well (1.), co-culture with ovarian cancer cells (2.) and VEGF-inhibition by addition of Flt1-Fc to both cell compartments (3.) (see also Herr
et al. 2012)
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Preparation of tissue for RNA-isolation
50–100 mg of the pulverized tumor- and peritoneal tissue
was mixed with 1 ml Trizol, incubated at room
temperature for 5 min and mixed with 200 μl chloroform.
After 3–5 min incubation at room temperature and cen-
trifugation the aqueous phase was mixed with 500 μl iso-
propanol and incubated for 5–15 min at 4 °C. After
centrifugation the pellet was washed twice with 1 ml 75 %
ethanol in DEPC-H2O and centrifuged for another 10 min
at 4 °C. Then the pellet was dispensed in RNA-free H2O
for 10 min at 55 °C. RNA was measured at the spectro-
photometer (Nanodrop 2000; Peqlab, Erlangen, Germany)
and stored at −80 °C.
RNA-Isolation
Total RNA from HUVEC, human ovarian cancer cells and
ovarian cancer tissue was extracted from cells with peq-
GOLD TriFast reagent (Peqlab, Erlangen, Germany). The
RNA product was quantified by absorbance at 260 nm
and total RNA (1.0 μg) was reverse transcribed into cDNA
using the cDNA High capacity Reverse Transcription kit
(Applied Biosystems, Foster City, USA) according to the
manufactures’s instructions.
Real-time-PCR
For quantification of VE-Cadherin and Claudin 5 expres-
sion Taqman Gene Expression Assays (VE-Cadherin:
Hs00174344_m1; Claudin 5: Hs00533949_s1; Applied
Biosystems by life technologies, Darmstadt, Germany)
were utilized according to the manufacturer’s instructions
using TaqMan™ Universal PCR Master Mix (Applied Bio-
systems by life technologies, Darmstadt, Germany). Amp-
lification and detection of specific products was
performed with Vii A 7™ Real-Time PCR System (Applied
Biosystems by life technologies, Darmstadt, Germany).
The quantity of cDNA was normalised to the quantity of
ß2-Microglobulin cDNA in each sample. Calculation of
relative gene expression was performed using the com-
parative 2-ΔΔCT method.
Statistics
Statistical analysis were performed using SPSS for
Windows version 21.0. The data distribution of most vari-
ables were significantly different from normal distribu-
tions; thus non-parametric statistical procedures were
used for all analyses presented here. Independent groups
were compared using Kruskal-Wallis and Mann–Whitney
U tests, while data obtained for samples of the same pa-
tients on different days were analysed with Friedman tests
and Wilcoxon matched pairs tests for related data. Com-
parisons among groups are illustrated using Box-and-
Whisker plots, where the horizontal line inside the box
represents the median and the box indicates the inter-
quartile range (IQR; the middle 50 % of scores). The ends
of the whiskers denote the lowest and highest values still
within 1.5 IQR of the lower and upper quartile (i.e. the
lower and upper end of the box), respectively. If there are
no values more than 1.5 IQR below the lower or above
the upper quartile (i.e. outliers), the ends of the whiskers
denote minimum and maximum of the data. Correlation
tests were performed using Spearman’s rank correlation
coefficient. All statistical tests were two-tailed and p-
values below 0.05 were considered to be statistically
significant.
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